

Biocare launches seven IVD antibodies

written by CAP TODAY

May 19, 2020

May 2020—Biocare Medical launched seven novel IVD IHC antibody markers for clinical diagnostics and research applications. This launch focuses on several immuno-oncology markers, critical in aiding early-stage cancer drug developments and patient treatment.

The company redeveloped its S100 protein antibody and released one mouse monoclonal and five novel rabbit monoclonal antibodies in the immuno-oncology space: CTLA-4 [CAL49], GITR [CAL8], LAG3 [CAL26], PD-1 [CAL20], CD22 (M) [BLCAM/1796], and E-cadherin [CDH1/2208R].

[Biocare Medical](#), 925-603-8000



©2026 CAP TODAY, all rights reserved.